RayzeBio, Inc. clinical trials
Acquired by Bristol-Myers Squibb, Feb 26, 2024 · source ↗
The registry lists 8 studies whose lead sponsor is RayzeBio, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Before and after it joined Bristol-Myers Squibb
- First submitted before RayzeBio, Inc. became part of Bristol-Myers Squibb
- 2
- First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- 6
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- RayzeBio, Inc.8 studies
Something wrong with this grouping? Tell us on the Bristol-Myers Squibb page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Bristol-Myers Squibb studies →
- RYZ711 Diagnostic Platform StudyNot yet recruitingNCT07862582Phase 1/2
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCRecruitingNCT07671092Early Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Imaging Study in Metastatic Clear Cell RCC.RecruitingNCT07671417Early Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCRecruitingNCT06726161Phase 1/2
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.RecruitingNCT07165132Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
Sponsor listed in the registry: RayzeBio, Inc. · First submitted before RayzeBio, Inc. became part of Bristol-Myers Squibb
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCActive, not recruitingNCT05595460Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted before RayzeBio, Inc. became part of Bristol-Myers Squibb